OCULOcular Therapeutix, Inc.

$6.50-47% 1Y

Is it safe?

Watch

Mixed picture: a safe balance sheet and clean books, but quality weak and heavy debt (BB).

2 good, 3 to watch, 1 neutral
SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Honest booksLow risk

Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Quality3 / 9

Weak, deteriorating fundamentals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Insider conviction-$568K

Insiders were net sellers (-$568K, 90 days to Oct 22, 2026), selling is often routine.

Credit gradeBBderived · Jun 30, 2026

Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.

Drawdown risk69% volderived · Oct 23, 2026

Large price swings, high volatility. Worst drawdown -91% · now 60% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitybehind 85% of the market
Max drawdownbehind 89% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can OCUL take a bad year?

Ocular Therapeutix, Inc. holds $526M more cash than debt, and is burning $64M a quarter, about 2.4 years of cover.

$526M

Net cash · as at Q2 2026 · cash and short-term investments less total debt

Net debt / EBITDA
net cash

Net debt / EBITDA · no net borrowings to measure against earnings

Altman Z-score
3.61

Altman Z-score · safe zone, above 3

Cash runway
2.4 years

Cash runway · burning $64M a quarter at the current rate

Details›
Total debtQ2 2026
$73M
Cash and short-term investments
$599M
Net cash
$526M
EBITDA, trailing twelve months
−$308M
Operating profit, trailing twelve months
−$314M
Debt / equity
0.14×
Annualised volatilitytwo years of daily moves
69%
Worst drawdown on file
−91%
Below its 52-week high
60%

Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.

The balance sheet

What it owes against what it owns, and how close that comes to trouble.

How far can it fall?

How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.

On our screens:Most shorted stocks